Stockholm, 19 October 2023. Redwood Pharma AB (publ) announces today that the company will participate in BIO-Europe, the life science industry’s largest investor and partnering meeting, in November 2023.
Redwood Pharma CEO Martin Vidaeus will attend BIO-Europe that will be held in Munich, Germany, between November 6-8. BIO-Europe is Europe’s leading partnering event with over 5,500 participants representing 60 countries and over 2,200 companies. The conference creates a unique opportunity for Redwood Pharma to engage in discussions with potential partners.
“After the summer, we received the final results from the RP501 clinical study. We will bring along the robust data package generated by the study to our discussions with potential partners. This meeting will provide us a favorable oppportunity to evaluate possible commercial partners in self-care and ophthalmology for a launch of the product in Europe,” says Redwood Pharma’s CEO, Martin Vidaeus.
RP501 is being developed to be an effective and user-friendly over-the-counter tear replacement agent for the temporary relief of dry eye, a condition that affects more than 300 million people worldwide. RP501 is based on IntelliGel – a patented and unique formulation that has the consistency of a drop of water when instilled onto the eye but immediately transforms into a viscous, protective and lubricating film that remains in the eye for a long period of time.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
About Redwood Pharma
Redwood Pharma AB (publ) (Nasdaq First North Growth Market: REDW) develops next-generation treatments for dry eye. More than 300 million people suffer from dry eyes and today’s standard treatment provides only temporary relief and may need to be applied more than ten times a day. Redwood Pharma’s programs are based on IntelliGel – a patented and unique formulation of polymers and water that has the consistency of a drop of water when dropped into the eye, where it immediately forms a viscous, protective and lubricating film that remains for a long time. The company is currently pursuing two development projects: RP501 as a readily available medical device for the first line treatment of dry eye, and the drug candidate RP101 that contains estrogen for the treatment of women who suffer from dry eye after menopause. The company’s Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm (+46 8 463 80 00, firstname.lastname@example.org). For more information, visit www.redwoodpharma.com